13 Jan 2026 • Real-world data from South India showed that an adalimumab biosimilar achieved substantial and sustained reductions in disease activity among patients with active axial spondyloarthritis, with no new safety risks.

Among 96 treated patients, more than half achieved meaningful clinical improvement within three months. By week 12, 54% reached a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 response, rising to 70% by week 24. Mean BASDAI scores fell from 5.8 at baseline to 2.9 at 12 weeks and 2.3 at 24 weeks. Despite prophylaxis, two incidences of TB were reported, but no significant adverse effects occurred.

The findings support the biosimilar as an effective, accessible alternative to originator biologics in routine care.

Source: IJMR | Read full story